Please login to the form below

Not currently logged in
Email:
Password:

Horizon

This page shows the latest Horizon news and features for those working in and with pharma, biotech and healthcare.

MHRA grants bluebird bio’s LentiGlobin gene therapy an ‘innovation passport’

MHRA grants bluebird bio’s LentiGlobin gene therapy an ‘innovation passport’

We’re thrilled to hear that another potential treatment option for sickle cell disease is on the horizon and wholeheartedly welcome the Innovative Licensing and Access Pathway Steering Group’s efforts

Latest news

More from news
Approximately 16 fully matching, plus 152 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 60 partially matching documents found.

Latest appointments

  • CureVac’s CEO appointed to EC High Level Group CureVac’s CEO appointed to EC High Level Group

    Dr Ingmar Hoerr will advise on Horizon 2020 and future innovation programmes. ... Dr Hoerr joins a panel of 15 group members who will advise the EC on how to strengthen support for breakthrough, market-creating innovation in the Horizon 2020 project as

  • Decibel Therapeutics expands leadership team Decibel Therapeutics expands leadership team

    He co-founded Bright Horizons Family Solutions, a worksite childcare and early education provider, and prior to this served as co-director of Save the Children's Sudan operations. .

  • Eric Rhodes becomes CEO of ERS Genomics Eric Rhodes becomes CEO of ERS Genomics

    Rhodes joins ERS Genomics from Horizon Discovery, where he served as senior vice president of research and development and chief technology officer. ... Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of

  • Jane Osbourn to chair BIA board Jane Osbourn to chair BIA board

    The new members of the board are Darrin Disley, chief executive of Horizon Discovery Group and David Hipkiss, chief business officer at Circassia Pharmaceuticals. Additionally Andrew Lightfood of Peptinnovate and Neil

  • Adaptimmune appoints Lawrence Alleva to its board Adaptimmune appoints Lawrence Alleva to its board

    He currently serves as a director for public companies Tesaro and Bright Horizons Family Solutions, and for the privately-held Mirna Therapeutics, and chairs those companies' audit committees.

More from appointments
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 35 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....